Supplementary Table 1. Five-year age-standardised net survival (95% CI) by country^a, period of diagnosis and morphological group^b

Italics denote net survival estimates that are not age-standardised.

Where two or more calendar periods of diagnosis were merged, the net survival estimates are underlined.

- ^a Countries with fewer than 10 women for any morphological group (all calendar periods combined) were not included in the analysis.
- ^b Only microscopically verified tumours or tumours with a clinical diagnosis but speific mophology code are included.
- ^c Endometrioid tumours are defined as type I epithelial.
- ^d Serous tumours are defined as type II epithelial.
- ^e Number of patients included in the analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from registries. The number of patients in each time period may differ from Table 4 due to merging of calendar periods.

Supplementary Table 2. Five-year age-standardised net survival (95% CI) by country^a, period of diagnosis for all tumours, tumours of known morphology^b and tumours of unknown morphology^b

Italics denote net survival estimates that are not age-standardised.

Where two or more calendar periods of diagnosis were merged, the net survival estimates are underlined.

- ^a Countries with fewer than 10 women for any morphological group (all calendar periods combined) were not included in the analysis.
- ^b Only microscopically verified tumours or tumours with a clinical diagnosis but speific mophology code are included.
- ^c Number of patients included in the analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from registries. The number of patients in each time period may differ from Table 3 due to merging of calendar periods.

Supplementary Table 3. Five-year age-standardised net survival (95% CI) by continent, country, registry^a calendar period and stage at diagnosis

Italics denote net survival estimates that are not age-standardised.

Where two or more calendar periods of diagnosis were merged, the net survival estimates are underlined.

- ^a Registries with fewer than 10 women for any stage (all calendar period combined) were not included in the analysis.
- ^b Number of patients included in analysis for a given calendar period. The number of women per registry may differ from the main CONCORD-2 analysis due to the exclusion of borderline tumours and updates from registries. The total number for a country in a given calendar period may not equal the sum of the number per registry for that period due to merging of calendar periods to produce the registry level estimates.

Supplementary Figure 1. Flow chat of data exclusions for analysis by morphological group

Supplementary Figure 2. Flow chat of data exclusions for analysis by stage at diagnosis